Camilla Fuchs Andersen retweetledi
OPEN ACCESS: Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program
pubmed.ncbi.nlm.nih.gov/38365073/
#Cardiology
English
Camilla Fuchs Andersen
5 posts
Camilla Fuchs Andersen
@FuchsAndersen
MD, currently employed as a PhD student at Herlev-Gentofte hospital
Katılım Nisan 2022
35 Takip Edilen39 Takipçiler
Camilla Fuchs Andersen retweetledi
The Empire Prevent trial program marks the first step towards elucidating the potential of SGLT2 inhibition for HF prevention 🫀🫀
Further reading: pubmed.ncbi.nlm.nih.gov/38365073/
@CardResearchOuh @HGHHjerte @RigsHeart @jhempelheart @FuchsAndersen @mortschou
English
Camilla Fuchs Andersen retweetledi
Empire Prevent 🩵🩷 includes patients in Odense @CardResearchOuh and Copenhagen @HGHHjerte. We greatly appreciate our collaboration with @SDCOdense and @RigsHeart 🩵🩷
English
Camilla Fuchs Andersen retweetledi
Patient #100 randomized in Empire Prevent
Empagliflozin to elderly and obese patients with cardiovascular disease (Empire Prevent): a randomized controlled trial.
Collaboration between @CardResearchOuh and @HGHHjerte.
English
Camilla Fuchs Andersen retweetledi
#HeartFailureAwarenessDays 2022!
Information campaign today at Herlev Hospital.
Conversations with visitors and employees. Focus on contacting your doctor and getting examined in case of suspect symptoms.
#HFAESC @HFA_President
@NinaNouhravesh @FuchsAndersen Lærke Nelson
English